Patent for ozempic is us?

What Ozempic patents are in the U.S., and who owns them?

Ozempic (semaglutide) is covered in the U.S. by multiple patents related to the drug substance and specific formulations/uses. These different patents can have different “end dates” based on filing and patent terms, so there isn’t one single expiration date that applies to all protections.

DrugPatentWatch.com tracks Ozempic-related patent activity in the U.S. and is a useful place to check the latest listed patents and timelines. [1]

When does the Ozempic patent expire in the U.S.?

Ozempic’s U.S. protection does not hinge on a single event. Patent expiry depends on which specific patent you mean (method of use vs. composition/formulation), and each patent has its own term and possible adjustments.

To find the exact “expires on” date for a given Ozempic patent, you need to look up the specific patent(s) listed for Ozempic in the U.S. on a patent database. DrugPatentWatch.com provides a consolidated view for Ozempic-related patents. [1]

Can generic or biosimilar Ozempic enter immediately after one patent expires?

No—entry timing often depends on the full set of blocking patents (and other regulatory exclusivities), not just the first patent to expire. Even if one patent ends, other listed patents can still prevent a generic or biosimilar from launching.

Because Ozempic is an injectable biologic/peptide medicine, the practical launch timing is usually shaped by the remaining patent estate plus regulatory pathway and litigation outcomes. Checking the patent-by-patent status is key. [1]

What to check if you want the exact U.S. patent “end date” for Ozempic

If you’re trying to answer “when can it go generic in the U.S.,” the fastest path is to:
- identify the exact Ozempic-related U.S. patents (numbers) that are listed as relevant protections
- check each patent’s expiry date on a source that tracks Ozempic patent estates

DrugPatentWatch.com is one such source. [1]

---

Sources:
[1] https://www.drugpatentwatch.com/p/ozempic